<p>瑞银资产管理（UBS AM），瑞银资产管理美洲有限公司（UBS ASSET MANAGEMENT AMERICAS LLC）的一家独立业务单位，在最近向证券交易委员会（SEC）提交的 13F 文件中披露，在第四季度增持了辉瑞公司（Pfizer Inc.，NYSE:PFE - 免费报告）4.4% 的股份。该基金在此期间额外收购了 1,517,551 股后，持有该生物制药公司 35,713,035 股股票。瑞银资产管理（UBS AM）在最近一个季度末持有辉瑞约 0.63% 的股份，价值 889,255,000 美元。</p>
<ul>
<li>专利悬崖掠夺者：GSK 以 106 亿美元收购 Nuvalent</li>
</ul>
<p>其他大型投资者也买卖了该公司的股票。Horizon Financial Services LLC 在第四季度将其在辉瑞的持仓增加了 174.8%。Horizon Financial Services LLC 目前持有辉瑞 1,014 股股票，价值 25,000 美元，此前在上个季度额外购买了 645 股。Godfrey Financial Associates Inc.在第四季度以 26,000 美元的价格新建了辉瑞的持仓。YANKCOM Partnership 在第四季度以 28,000 美元的价格新建了辉瑞的持仓。HFM Investment Advisors LLC 在第四季度将其在辉瑞的持仓增加了 61.0%。HFM Investment Advisors LLC 目前持有辉瑞 1,127 股股票，价值 28,000 美元，此前在上个季度额外购买了 427 股。最后，Darwin Wealth Management LLC 在第二季度以 32,000 美元的价格新建了辉瑞的持仓。目前 68.36% 的股票由机构投资者持有。</p>
<h2>辉瑞新闻汇总</h2>
<p>以下是本周影响辉瑞的主要新闻：</p>
<ul>
<li>积极情绪：辉瑞的新减肥数据被视为对其肥胖业务的鼓舞，可能改善其管线的竞争案例，并帮助未来增长的情绪。文章标题</li>
<li>积极情绪：辉瑞针对 HYMPAVZI 的美国标签扩展增加了对血友病业务的乐观情绪，扩大了可服务的患者群体，这可能支持未来的特种药物销售。文章标题</li>
<li>积极情绪：RBC 最近将辉瑞评级上调至行业表现，称估值已重置，风险回报特征在管线催化剂之前看起来更为平衡。文章标题</li>
<li>积极情绪：一些近期文章认为辉瑞的 Seagen 肿瘤学平台和新收购的肥胖资产可能有助于抵消专利到期和后 COVID 的收入压力，支持长期反转的论点。文章标题</li>
<li>中性情绪：分析师目前对辉瑞的平均评级为持有，表明市场在更多管线和商业执行证明之前，看到有限的短期上行空间。文章标题</li>
<li>消极情绪：看跌评论继续强调辉瑞的股息收益率作为对现金流、债务和公司支持股息和再投资能力的潜在担忧的标志。文章标题</li>
</ul>
<h2>华尔街分析师观点</h2>
<ul>
<li>应对大型制药专利悬崖的两种方式</li>
</ul>
<p>多位研究分析师对辉瑞股票发表了评论。Zacks Research 在 2 月 24 日的研究报告中将辉瑞的评级从 “强烈卖出” 上调至 “持有”。Wolfe Research 在 5 月 14 日的研究报告中重申了 “表现不佳” 的评级，并对辉瑞的股票设定了 26.00 美元的目标价。美国银行在 4 月 9 日的研究报告中将辉瑞的目标价从 27.00 美元下调至 26.00 美元，并对该股票设定了 “中性” 评级。瑞银集团在 5 月 27 日的研究报告中重申了 “中性” 评级，并对辉瑞的股票设定了 27.00 美元的目标价。最后，花旗集团在 4 月 29 日的研究报告中将辉瑞的目标价从 26.00 美元上调至 27.00 美元，并给予公司 “中性” 评级。一位投资分析师对该股票给予了强烈买入评级，五位给予买入评级，十二位给予持有评级，两位给予卖出评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “持有”，共识目标价为 28.82 美元。</p>
<p><strong>阅读我们最新的辉瑞股票分析</strong></p>
<h2>辉瑞股票表现</h2>
<ul>
<li>5 只高收益股票，保护您的投资组合免受风暴影响</li>
</ul>
<p>辉瑞股票周五开盘价为 26.19 美元。该公司的市值为 1492.6 亿美元，市盈率为 19.99，贝塔系数为 0.34。辉瑞公司 12 个月低点为 23.11 美元，12 个月高点为 28.75 美元。该公司的流动比率为 1.25，速动比率为 0.94，债务与股本比率为 0.67。该股票的 50 日简单移动平均线为 26.43 美元，200 日简单移动平均线为 26.32 美元。</p>
<p>辉瑞（NYSE:PFE - 获取免费报告）最近在 5 月 5 日发布了季度财报。该生物制药公司报告季度每股收益（EPS）为 0.75 美元，超出市场共识预期的 0.72 美元，超出 0.03 美元。该业务的季度收入为 144.5 亿美元，而市场共识预期为 138.4 亿美元。辉瑞的股本回报率为 19.44%，净利润率为 11.83%。该公司的收入较去年同期增长了 5.4%。去年同期，该业务的每股收益为 0.92 美元。辉瑞已将其 2026 财年的指导目标设定为 2.800-3.000 每股收益。研究分析师平均预测辉瑞公司今年的每股收益为 2.99 美元。</p>
<h2>辉瑞宣布分红</h2>
<p>该公司最近还披露了季度分红，已于 6 月 12 日支付。5 月 8 日的登记投资者每股获得 0.43 美元的分红。这代表着每年 1.72 美元的分红，收益率为 6.6%。该分红的除息日期为 5 月 8 日。辉瑞的分红支付比率（DPR）目前为 131.30%。</p>
<h2>辉瑞公司简介</h2>
<p>（免费报告）</p>
<p>辉瑞公司（Pfizer Inc）在纽约证券交易所上市，股票代码为 PFE，是一家总部位于纽约市的跨国生物制药公司。公司成立于 1849 年，由查尔斯·辉瑞（Charles Pfizer）和查尔斯·厄哈特（Charles Erhart）创立，专注于人类健康的药物和疫苗的研究、开发、生产和商业化。其业务涵盖发现研究、临床开发、监管事务、制造和全球商业分销，涉及多个治疗领域。</p>
<p>辉瑞的产品组合和研发管线涵盖肿瘤学、免疫学、心脏病学、内分泌学、罕见疾病、医院急救和抗感染药物，以及一个可观的疫苗业务。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们认为比辉瑞更好的股票</li>
<li>SpaceX 敲响开盘钟，打破所有记录</li>
<li>Adobe 股票刚刚变便宜——华尔街是否忽视了这个故事？</li>
<li>三只低于 50 美元的分红股票，支付你等待通胀的时间</li>
<li>127 吉瓦的问题：为什么人工智能需要自己的电力</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在辉瑞吗？</h2>
<p>在考虑辉瑞之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而辉瑞并不在名单上。</p>
<p>虽然辉瑞目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

辉瑞

瑞银集团

<p>瑞银资产管理在第四季度将其辉瑞的持股增加了 4.4%，收购了 1,517,551 股，总持股达到 3570 万股，价值约为 8.893 亿美元。其他投资者如 Horizon Financial 也增加了持仓。分析师的情绪仍然不一；Zacks 将辉瑞评级上调至 “持有”，而其他分析师则维持中性或表现不佳的评级，目标价在 26 至 27 美元之间。该股票目前交易价格接近 26.19 美元，市场共识目标价为 28.82 美元</p>

<p>UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 4.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 35,713,035 shares of the biopharmaceutical company's stock after acquiring an additional 1,517,551 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.63% of Pfizer worth $889,255,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>瑞银资产管理（UBS AM），瑞银资产管理美洲有限公司（UBS ASSET MANAGEMENT AMERICAS LLC）的一家独立业务单位，在最近向证券交易委员会（SEC）提交的 13F 文件中披露，在第四季度增持了辉瑞公司（Pfizer Inc.，NYSE:PFE - 免费报告）4.4% 的股份。该基金在此期间额外收购了 1,517,551 股后，持有该生物制药公司 35,713,035 股股票。瑞银资产管理（UBS AM）在最近一个季度末持有辉瑞约 0.63% 的股份，价值 889,255,000 美元。</p>
</div><ul>
<li>Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion</li>
</ul>
<div class="lb-trans"><ul>
<li>专利悬崖掠夺者：GSK 以 106 亿美元收购 Nuvalent</li>
</ul>
</div><p>Other large investors have also bought and sold shares of the company. Horizon Financial Services LLC boosted its position in Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 645 shares during the last quarter. Godfrey Financial Associates Inc. bought a new position in Pfizer in the 4th quarter valued at $26,000. YANKCOM Partnership bought a new position in Pfizer in the 4th quarter valued at $28,000. HFM Investment Advisors LLC boosted its position in Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 427 shares during the last quarter. Finally, Darwin Wealth Management LLC bought a new position in Pfizer in the 2nd quarter valued at $32,000. 68.36% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他大型投资者也买卖了该公司的股票。Horizon Financial Services LLC 在第四季度将其在辉瑞的持仓增加了 174.8%。Horizon Financial Services LLC 目前持有辉瑞 1,014 股股票，价值 25,000 美元，此前在上个季度额外购买了 645 股。Godfrey Financial Associates Inc.在第四季度以 26,000 美元的价格新建了辉瑞的持仓。YANKCOM Partnership 在第四季度以 28,000 美元的价格新建了辉瑞的持仓。HFM Investment Advisors LLC 在第四季度将其在辉瑞的持仓增加了 61.0%。HFM Investment Advisors LLC 目前持有辉瑞 1,127 股股票，价值 28,000 美元，此前在上个季度额外购买了 427 股。最后，Darwin Wealth Management LLC 在第二季度以 32,000 美元的价格新建了辉瑞的持仓。目前 68.36% 的股票由机构投资者持有。</p>
</div><h2>Pfizer News Roundup</h2>
<div class="lb-trans"><h2>辉瑞新闻汇总</h2>
</div><p>Here are the key news stories impacting Pfizer this week:</p>
<div class="lb-trans"><p>以下是本周影响辉瑞的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: Pfizer’s new weight-loss data is being viewed as encouraging for its obesity franchise, potentially improving the competitive case for its pipeline and helping sentiment around future growth. Article Title</li>
<li>Positive Sentiment: Pfizer’s expanded U.S. label for HYMPAVZI is adding to optimism around the hemophilia business by widening the addressable patient pool, which may support future specialty-drug sales. Article Title</li>
<li>Positive Sentiment: RBC recently upgraded Pfizer to Sector Perform, saying the valuation has reset and the risk-reward profile looks more balanced ahead of pipeline catalysts. Article Title</li>
<li>Positive Sentiment: Some recent articles argue Pfizer’s Seagen oncology platform and newly acquired obesity assets could help offset patent-expiry and post-COVID revenue pressure, supporting a long-term turnaround thesis. Article Title</li>
<li>Neutral Sentiment: Analysts currently rate Pfizer around Hold on average, suggesting the market sees limited near-term upside until more pipeline and commercial execution proves out. Article Title</li>
<li>Negative Sentiment: Bearish commentary continues to highlight Pfizer’s dividend yield as a sign of underlying concern about cash flow, debt, and the company’s ability to support both payouts and reinvestment. Article Title</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：辉瑞的新减肥数据被视为对其肥胖业务的鼓舞，可能改善其管线的竞争案例，并帮助未来增长的情绪。文章标题</li>
<li>积极情绪：辉瑞针对 HYMPAVZI 的美国标签扩展增加了对血友病业务的乐观情绪，扩大了可服务的患者群体，这可能支持未来的特种药物销售。文章标题</li>
<li>积极情绪：RBC 最近将辉瑞评级上调至行业表现，称估值已重置，风险回报特征在管线催化剂之前看起来更为平衡。文章标题</li>
<li>积极情绪：一些近期文章认为辉瑞的 Seagen 肿瘤学平台和新收购的肥胖资产可能有助于抵消专利到期和后 COVID 的收入压力，支持长期反转的论点。文章标题</li>
<li>中性情绪：分析师目前对辉瑞的平均评级为持有，表明市场在更多管线和商业执行证明之前，看到有限的短期上行空间。文章标题</li>
<li>消极情绪：看跌评论继续强调辉瑞的股息收益率作为对现金流、债务和公司支持股息和再投资能力的潜在担忧的标志。文章标题</li>
</ul>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><ul>
<li>2 Ways to Play the Big Pharma Patent Cliff</li>
</ul>
<div class="lb-trans"><ul>
<li>应对大型制药专利悬崖的两种方式</li>
</ul>
</div><p>A number of research analysts have commented on PFE shares. Zacks Research upgraded Pfizer from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, February 24th. Wolfe Research reissued an &#34;underperform&#34; rating and issued a $26.00 price target on shares of Pfizer in a research note on Thursday, May 14th. Bank of America cut their price target on Pfizer from $27.00 to $26.00 and set a &#34;neutral&#34; rating on the stock in a research note on Thursday, April 9th. UBS Group reissued a &#34;neutral&#34; rating and issued a $27.00 price target on shares of Pfizer in a research note on Wednesday, May 27th. Finally, Citigroup increased their price target on Pfizer from $26.00 to $27.00 and gave the company a &#34;neutral&#34; rating in a research note on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of &#34;Hold&#34; and a consensus target price of $28.82.</p>
<div class="lb-trans"><p>多位研究分析师对辉瑞股票发表了评论。Zacks Research 在 2 月 24 日的研究报告中将辉瑞的评级从 “强烈卖出” 上调至 “持有”。Wolfe Research 在 5 月 14 日的研究报告中重申了 “表现不佳” 的评级，并对辉瑞的股票设定了 26.00 美元的目标价。美国银行在 4 月 9 日的研究报告中将辉瑞的目标价从 27.00 美元下调至 26.00 美元，并对该股票设定了 “中性” 评级。瑞银集团在 5 月 27 日的研究报告中重申了 “中性” 评级，并对辉瑞的股票设定了 27.00 美元的目标价。最后，花旗集团在 4 月 29 日的研究报告中将辉瑞的目标价从 26.00 美元上调至 27.00 美元，并给予公司 “中性” 评级。一位投资分析师对该股票给予了强烈买入评级，五位给予买入评级，十二位给予持有评级，两位给予卖出评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “持有”，共识目标价为 28.82 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on Pfizer</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的辉瑞股票分析</strong></p>
</div><h2>Pfizer Stock Performance</h2>
<div class="lb-trans"><h2>辉瑞股票表现</h2>
</div><ul>
<li>5 High-Yield Stocks to Shield Your Portfolio From the Storm</li>
</ul>
<div class="lb-trans"><ul>
<li>5 只高收益股票，保护您的投资组合免受风暴影响</li>
</ul>
</div><p>Shares of Pfizer stock opened at $26.19 on Friday. The company has a market capitalization of $149.26 billion, a PE ratio of 19.99 and a beta of 0.34. Pfizer Inc. has a 12 month low of $23.11 and a 12 month high of $28.75. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The stock's fifty day simple moving average is $26.43 and its 200 day simple moving average is $26.32.</p>
<div class="lb-trans"><p>辉瑞股票周五开盘价为 26.19 美元。该公司的市值为 1492.6 亿美元，市盈率为 19.99，贝塔系数为 0.34。辉瑞公司 12 个月低点为 23.11 美元，12 个月高点为 28.75 美元。该公司的流动比率为 1.25，速动比率为 0.94，债务与股本比率为 0.67。该股票的 50 日简单移动平均线为 26.43 美元，200 日简单移动平均线为 26.32 美元。</p>
</div><p>Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm's revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts predict that Pfizer Inc. will post 2.99 EPS for the current year.</p>
<div class="lb-trans"><p>辉瑞（NYSE:PFE - 获取免费报告）最近在 5 月 5 日发布了季度财报。该生物制药公司报告季度每股收益（EPS）为 0.75 美元，超出市场共识预期的 0.72 美元，超出 0.03 美元。该业务的季度收入为 144.5 亿美元，而市场共识预期为 138.4 亿美元。辉瑞的股本回报率为 19.44%，净利润率为 11.83%。该公司的收入较去年同期增长了 5.4%。去年同期，该业务的每股收益为 0.92 美元。辉瑞已将其 2026 财年的指导目标设定为 2.800-3.000 每股收益。研究分析师平均预测辉瑞公司今年的每股收益为 2.99 美元。</p>
</div><h2>Pfizer Announces Dividend</h2>
<div class="lb-trans"><h2>辉瑞宣布分红</h2>
</div><p>The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 12th. Investors of record on Friday, May 8th were paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.6%. The ex-dividend date of this dividend was Friday, May 8th. Pfizer's dividend payout ratio (DPR) is presently 131.30%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度分红，已于 6 月 12 日支付。5 月 8 日的登记投资者每股获得 0.43 美元的分红。这代表着每年 1.72 美元的分红，收益率为 6.6%。该分红的除息日期为 5 月 8 日。辉瑞的分红支付比率（DPR）目前为 131.30%。</p>
</div><h2>Pfizer Company Profile</h2>
<div class="lb-trans"><h2>辉瑞公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.</p>
<div class="lb-trans"><p>辉瑞公司（Pfizer Inc）在纽约证券交易所上市，股票代码为 PFE，是一家总部位于纽约市的跨国生物制药公司。公司成立于 1849 年，由查尔斯·辉瑞（Charles Pfizer）和查尔斯·厄哈特（Charles Erhart）创立，专注于人类健康的药物和疫苗的研究、开发、生产和商业化。其业务涵盖发现研究、临床开发、监管事务、制造和全球商业分销，涉及多个治疗领域。</p>
</div><p>Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.</p>
<div class="lb-trans"><p>辉瑞的产品组合和研发管线涵盖肿瘤学、免疫学、心脏病学、内分泌学、罕见疾病、医院急救和抗感染药物，以及一个可观的疫苗业务。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Pfizer</li>
<li>SpaceX Rings the Bell and Shatters Every Record</li>
<li>Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?</li>
<li>3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation</li>
<li>The 127-Gigawatt Problem: Why AI Needs Its Own Power</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比辉瑞更好的股票</li>
<li>SpaceX 敲响开盘钟，打破所有记录</li>
<li>Adobe 股票刚刚变便宜——华尔街是否忽视了这个故事？</li>
<li>三只低于 50 美元的分红股票，支付你等待通胀的时间</li>
<li>127 吉瓦的问题：为什么人工智能需要自己的电力</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=PFE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Pfizer Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在辉瑞吗？</h2>
</div><p>Before you consider Pfizer, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑辉瑞之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而辉瑞并不在名单上。</p>
</div><p>While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然辉瑞目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 1,517,551 Shares of Pfizer Inc. $PFE

- UBS AM 增持 Pfizer 股票 4.4%，持股达 3571 万股，市值 8.89 亿美元。  
- Horizon Financial Services 增持 174.8%，现持有 1014 股，市值 2.5 万美元。  
- Pfizer 第四季度营收增 5.4%，每股收益 0.75 美元，超过预期。

Market Beat

葛兰素史克

Nuvalent

加拿大皇家银行

美国银行

花旗

GSK plc Sponsored ADR

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

CITIGROUP INC 6.250 NON CUM SER II PFD WI

瑞银资产管理美洲有限责任公司（UBS ASSET MANAGEMENT AMERICAS LLC）旗下的独立业务单元 UBS AM 收购了辉瑞公司（Pfizer Inc.）1,517,551 股股票